These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 22728007)

  • 21. [Molecular targeted therapy for breast cancer treatment, challenge to cure].
    Yamashiro H; Toi M
    Nihon Rinsho; 2010 Oct; 68(10):1854-8. PubMed ID: 20954329
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment.
    Conte P; Guarneri V; Bengala C
    Clin Breast Cancer; 2007 Dec; 7(11):841-9. PubMed ID: 18269773
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dual HER2-targeted approaches in HER2-positive breast cancer.
    Ahn ER; Vogel CL
    Breast Cancer Res Treat; 2012 Jan; 131(2):371-83. PubMed ID: 21956210
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
    Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
    Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
    Burris HA; Rugo HS; Vukelja SJ; Vogel CL; Borson RA; Limentani S; Tan-Chiu E; Krop IE; Michaelson RA; Girish S; Amler L; Zheng M; Chu YW; Klencke B; O'Shaughnessy JA
    J Clin Oncol; 2011 Feb; 29(4):398-405. PubMed ID: 21172893
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Progression and treatment of HER2-positive breast cancer.
    Davoli A; Hocevar BA; Brown TL
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Making real progress against breast cancer. Some of the best cancer news this year has been the success of targeted approaches to treating breast cancer.
    Harv Womens Health Watch; 2005 Oct; 13(2):1-3. PubMed ID: 16320417
    [No Abstract]   [Full Text] [Related]  

  • 28. Resistance to HER2 inhibitors: is addition better than substitution? Rationale for the hypothetical concept of drug sedimentation.
    Campone M; Juin P; André F; Bachelot T
    Crit Rev Oncol Hematol; 2011 Jun; 78(3):195-205. PubMed ID: 20684884
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy.
    Meric-Bernstam F; Hung MC
    Clin Cancer Res; 2006 Nov; 12(21):6326-30. PubMed ID: 17085641
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer.
    Spector NL; Blackwell KL
    J Clin Oncol; 2009 Dec; 27(34):5838-47. PubMed ID: 19884552
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeted cancer therapies.
    Blay JY; Le Cesne A; Alberti L; Ray-Coquart I
    Bull Cancer; 2005 Feb; 92(2):E13-8. PubMed ID: 15749638
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Supports for the toxicity of the molecular target medicine].
    Inoue K
    Nihon Rinsho; 2012 Sep; 70 Suppl 7():678-86. PubMed ID: 23350485
    [No Abstract]   [Full Text] [Related]  

  • 33. Molecularly targeted therapeutics for breast cancer.
    Hussain SA; Palmer DH; Spooner D; Rea DW
    BioDrugs; 2007; 21(4):215-24. PubMed ID: 17628119
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Resistant mechanisms against breast cancer treatment and therapeutic strategies].
    Tanizaki J; Tsurutani J
    Nihon Rinsho; 2012 Nov; 70 Suppl 8():336-40. PubMed ID: 23513862
    [No Abstract]   [Full Text] [Related]  

  • 35. Women survive breast cancer but fall victim to heart failure: the shadows and lights of targeted therapy.
    Maurea N; Coppola C; Ragone G; Frasci G; Bonelli A; Romano C; Iaffaioli RV
    J Cardiovasc Med (Hagerstown); 2010 Dec; 11(12):861-8. PubMed ID: 20072001
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Next-generation targeted agents in HER2-positive metastatic breast cancer.
    Perez EA
    Clin Adv Hematol Oncol; 2012 Jul; 10(7):465-7. PubMed ID: 22895288
    [No Abstract]   [Full Text] [Related]  

  • 37. Targeted Therapies in the Treatment of Breast Cancer. Proceedings of a meeting. Kailua-Kona, Hawaii, July 19-23, 2000.
    Semin Oncol; 2001 Oct; 28(5 Suppl 16):1-153; quiz 154-65. PubMed ID: 11760720
    [No Abstract]   [Full Text] [Related]  

  • 38. Understanding the value of antiangiogenic therapy in metastatic breast cancer.
    Martín M
    Curr Opin Oncol; 2011 Apr; 23 Suppl():S1. PubMed ID: 21490479
    [No Abstract]   [Full Text] [Related]  

  • 39. [The role of avastin in the treatment of breast carcinoma in Europe and the United States].
    Rajnohová H; Nový F
    Klin Onkol; 2011; 24(1):56. PubMed ID: 21542278
    [No Abstract]   [Full Text] [Related]  

  • 40. [Progress of molecularly targeted therapy for breast cancer].
    Ito Y
    Rinsho Ketsueki; 2012 Apr; 53(4):426-32. PubMed ID: 22687976
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.